Transaction in Own Shares

Summary by AI BETAClose X

Fevertree Drinks plc has announced the purchase of 158,776 ordinary shares between August 24th and August 28th, 2026, as part of its share buyback program. The volume-weighted average price for these purchases ranged from 851.21p to 858.07p, with individual share prices varying between 843.50p and 864.50p. The company intends to cancel these repurchased shares.

Disclaimer*

Fevertree Drinks PLC
02 September 2026
 

2nd September 2026                              

Fevertree Drinks plc

("Fever-Tree" or the "Company")

Transaction in Own Shares

 

Fevertree Drinks plc ("Fever-Tree" or the "Company") announces today it has, in accordance with the authority granted by shareholders at its 2025 Annual General Meeting held on 5th June, purchased the following number of ordinary shares of £0.0025 each in the Company (the "Ordinary Shares") through the Company's broker, Investec Bank plc ("Investec") in the period from 24th August to 28th August 2026.

Date

Venue

Volume-weighted average price (p)

Aggregated volume

Lowest price per share (p)

Highest price per share (p)

24 August 2026

XLON

857.2174

9,189

851.5000

864.5000

24 August 2026

AIMX

858.0662

44,565

857.5000

858.5000

25 August 2026

XLON

851.2110

21,598

843.5000

858.0000

25 August 2026

AIMX

857.0000

30,000

857.0000

857.0000

26 August 2026

XLON

860.8649

14,129

853.0000

864.5000

27 August 2026

XLON

853.6912

17,213

849.5000

858.5000

27 August 2026

AIMX

854.5000

9,000

854.5000

854.5000

28 August 2026

XLON

858.3591

23,175

849.5000

861.5000

 

The Company intends to cancel the purchased shares.

   

Schedule of Purchases - Individual Transactions

In accordance with Article 5(1)(b) of Regulation (EU) No 596/2014 (the Market Abuse Regulation) (which forms part of domestic UK law by virtue of the European Union (Withdrawal) Act 2018, as amended), a full breakdown of the individual trades made by Investec on behalf of the Company as part of the share buyback programme is attached to this announcement.

 

http://www.rns-pdf.londonstockexchange.com/rns/8819S_1-2026-9-1.pdf

 

This announcement does not constitute, or form part of, an offer or any solicitation of an offer for securities in any jurisdiction.

 

For further information please contact:

 

Investor queries

Steve Nightingale, Director of Investor Relations I steve.nightingale@fever-tree.com I +44 (0)7951 849564

 

Media queries

Oliver Winters, Director of Communications I oliver.winters@fever-tree.com I +44 (0)770 332 9024  

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
UK 100

Latest directors dealings